# A Study to Investigate Safety and Tolerability of SH3765 Tablet in Patients With Advanced Malignant Tumor

> **NCT05015309** · PHASE1 · UNKNOWN · sponsor: **Nanjing Sanhome Pharmaceutical, Co., Ltd.** · enrollment: 40 (estimated)

## Conditions studied

- Advanced Malignant Tumor

## Interventions

- **DRUG:** SH3765 tablet

## Key facts

- **NCT ID:** NCT05015309
- **Lead sponsor:** Nanjing Sanhome Pharmaceutical, Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-09
- **Primary completion:** 2023-03
- **Final completion:** 2024-09
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2021-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05015309

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05015309, "A Study to Investigate Safety and Tolerability of SH3765 Tablet in Patients With Advanced Malignant Tumor". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05015309. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*